Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2025 Feb 1;57(2):327-336.
doi: 10.1249/MSS.0000000000003559. Epub 2024 Sep 18.

Evaluating the Impact of Post-Esophagectomy Exercise on 2- and 5-Yr Survival: Findings from the PERFECT Trial

David Binyam  1 , Jonna K VAN Vulpen  2 , Richard VAN Hillegersberg  3 , Jelle P Ruurda  3 , Grard A P Nieuwenhuijzen  4 , Ewout A Kouwenhoven  5 , Elsken VAN DER Wall  6 , Richard P R Groenendijk  7 , Donald L VAN DER Peet  8 , Camiel Rosman  9 , Bas P L Wijnhoven  10 , Mark I VAN Berge Henegouwen, Hanneke W M VAN Laarhoven, Peter D Siersema  11 , Anne M May  1 , Anouk E Hiensch  1
Affiliations
Randomized Controlled Trial

Evaluating the Impact of Post-Esophagectomy Exercise on 2- and 5-Yr Survival: Findings from the PERFECT Trial

David Binyam et al. Med Sci Sports Exerc. .

Abstract

Purpose: Despite recent treatment advances, esophageal cancer still has poor survival and a high morbidity. Exploratory evidence suggests that exercise can reduce cancer-related mortality and recurrence rates. Here, we investigated the effects of an exercise intervention in the first year after esophagectomy on survival in participants of the Physical ExeRcise Following Esophageal Cancer Treatment (PERFECT) trial.

Methods: In the PERFECT trial, esophageal cancer patients who had undergone esophagectomy were randomized to a 12-wk exercise program (EX) or the control group (CG). We assessed 2- and 5-yr (progression-free) survival. (Un)adjusted Cox proportional-hazards models were used to calculate hazard ratios (HRs) for comparison between the trial arms. Sensitivity analyses, excluding patients with events within the exercise intervention period, were performed.

Results: In total, 120 participants (EX = 61; CG = 59) were included in the PERFECT trial. After 2-yr follow-up, no significant difference in the risk of death or progression between EX and CG was found (adjusted HR = 1.65 (95% confidence interval (CI), 0.75-3.63) and 1.38 (95% CI, 0.76-2.50), respectively). After excluding patients with events during the intervention period (EX = 8; CG = 4), 2-yr HRs for death (1.03; 95% CI, 0.41-2.56) and progression (1.26; 95% CI, 0.64-2.48) both decreased and remained insignificant. No significant effects were found on 5-yr mortality (1.03; 95% CI, 0.57-1.84) and progression (1.21; 95% CI, 0.72-2.04) either. Sensitivity analysis resulted in attenuated 5-yr HRs for mortality (0.82; 95% CI, 0.42-1.58) and progression (1.08; 95% CI, 0.61-1.92).

Conclusions: The results indicate no benefit of a 12-wk exercise program in the first year post-esophagectomy on 2- and 5-yr (progression-free) survival in esophageal cancer patients. The absence of beneficial effects may be explained by the relatively short exercise program, which was performed after treatment completion.

PubMed Disclaimer

References

    1. Ferlay J, Colombet M, Soerjomataram I, et al. Estimating the global cancer incidence and mortality in 2018: GLOBOCAN sources and methods. Int J Cancer . 2019;144(98):1941–53.
    1. Shapiro J, van Lanschot JJB, Hulshof MCCM, et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): long-term results of a randomised controlled trial. Lancet Oncol . 2015;16(9):1090–8.
    1. Gottlieb-Vedi E, Kauppila JH, Malietzis G, Nilsson M, Markar SR, Lagergren J. Long-term survival in esophageal cancer after minimally invasive compared to open esophagectomy: a systematic review and meta-analysis. Ann Surg . 2019;270(6):1005–17.
    1. van Putten M, de Vos-Geelen J, Nieuwenhuijzen GAP, et al. Long-term survival improvement in oesophageal cancer in the Netherlands. Eur J Cancer . 2018;94:138–47.
    1. Kuijper SC, Pape M, Vissers PAJ, et al. Trends in best-case, typical and worst-case survival scenarios of patients with non-metastatic esophagogastric cancer between 2006 and 2020: a population-based study. Int J Cancer . 2023;153(1):33–43.

Publication types

LinkOut - more resources